 Lynx Therapeutics, Inc. |
| Alliances with: |
- Aventis
CropScience
- DuPont
|
|
|
Lynx Therapeutics, Inc. is a leader
in the development and application of novel technologies for the
discovery of gene expression patterns and genomic variations important
to the pharmaceutical, biotechnology and agricultural industries. These
technologies are based on the Megaclone(TM) technology, Lynx's unique
and proprietary cloning procedure, which transforms a sample containing
millions of DNA molecules into one made up of millions of micro-beads,
each of which carries approximately 100,000 copies of one of the DNA
molecules in the sample. Megaclone(TM) technology is the foundation for
Lynx's analytical applications, including: Massively Parallel Signature
Sequencing, or MPSS(TM), technology, which provides gene sequence
information and high-resolution gene expression data; Megasort(TM)
technology, which provides differentially expressed gene sets; and
Megatype(TM) technology, which provides single nucleotide polymorphism,
or SNP, disease- or trait-association information. Lynx is also
developing a proteomics technology, Protein ProFiler(TM), which is
expected to provide high-resolution analysis of complex mixtures of
proteins from cells or tissues. |
|
25861 Industrial Boulevard - Hayward, CA 94545 - USA - Tel: +1 [510] 670-9300 Fax:
[510] 670-9302 |
|
